Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Destiny Pharma. Share Price
  4. Destiny Pharma. Share Regulatory News
  5. Destiny Pharma to join panel discussion at LSX

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Destiny Pharma. Information

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.00
Bid: 10.50
Ask: 11.50
Change: 0.50 (4.76%)
Spread: 1.00 (9.524%)
Open: 10.50
High: 11.00
Low: 10.50
Prev. Close: 10.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Destiny Pharma to join panel discussion at LSX

2 Feb 2021 07:05

RNS Number : 6222N
Destiny Pharma PLC
02 February 2021
 

Destiny Pharma PLC

("Destiny" or "the Company")

 

 

Destiny Pharma to Participate in Panel Discussion at the

7th Annual LSX World Congress 2021

 

 

Brighton, UK, 2 February 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that Neil Clark, Chief Executive Officer, will be taking part in a panel discussion at the 7th Annual LSX World Congress to be held virtually between 1-5 February, 2021.

 

The panel discussion 'Investing In Infectious Disease - How Will The Covid Pandemic Transform The Development, Commercialisation, And Partnering Landscape?' will be held at 15:00 GMT on 2nd February 2021.

 

The panel will be made available through the conference website and will be available to registered participants throughout the event - www.lsxleaders.com/lsx-world-congress.

 

- Ends -

 

Enquiries:

 

Destiny Pharma plc

+44 (0) 1273 704 440

Neil Clark (Chief Executive Officer)

Shaun Claydon (Chief Financial Officer and Company Secretary)

 

finnCap Limited - Nominated Adviser and Joint Broker

+44 (0) 20 7220 0500

Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)

Alice Lane (ECM)

 

WG Partners LLP - Joint Broker

+44 (0) 20 3705 9330

Nigel Barnes / Claes Spång / Nigel Birks / Andrew Craig

 

Optimum Strategic Communication

+44 (0) 203 174 1789

Mary Clark / Shabnam Bashir / Manel Mateus

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

 

For further information, please visit https://www.destinypharma.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFERFAILIIL
12345
Date   Source Headline
22nd Dec 20229:05 amRNSSecond Price Monitoring Extn
22nd Dec 20229:00 amRNSPrice Monitoring Extension
22nd Dec 20227:00 amRNSYear End Trading Update
7th Dec 20227:00 amRNSFDA/CDC highlight need for infection preventions
7th Dec 20227:00 amRNSXF-73 Nasal final Phase 3 development plans
2nd Dec 20222:48 pmRNSDirector Disclosure
23rd Nov 20227:00 amRNSAppointment of Corporate Broker
21st Nov 20222:20 pmEQSDestiny Pharma PLC 'leads the world' in new approach to preventing hospital infections
18th Nov 20221:16 pmRNSDirector Shareholding Amendment
15th Nov 20227:00 amRNSXF-73 advances to clinically enabling safety study
31st Oct 202211:06 amRNSSecond Price Monitoring Extn
31st Oct 202211:01 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSNotice of R&D Update Meeting
8th Sep 20227:00 amRNSInterim results for six months ended 30 June 2022
7th Sep 20227:03 amRNSPresenting at HC Wainwright Investment Conference
7th Sep 20227:01 amRNSPositive update from EMA on NTCD-M3 Phase 3 plans
5th Sep 20222:15 pmRNSExpiry of Share Options
22nd Aug 20227:00 amRNSNotice of Interim Results
28th Jul 20227:00 amRNSChair’s Investor Update
26th Jul 20227:00 amRNSPublication of new data on NTCD-M3
19th Jul 20227:00 amRNSPositive update from US FDA on XF-73 Phase 3
12th Jul 20227:00 amRNSGrant from the Cystic Fibrosis Foundation
7th Jul 20227:00 amRNSPublication of XF-73 drug synergy data
5th Jul 20227:00 amRNSNew XF-73 research programme
8th Jun 20227:00 amRNSGrant of share options
27th May 202211:56 amRNSResult of Annual General Meeting & Strategy Update
26th May 20227:00 amRNSBoard Changes
12th May 20227:00 amRNSLandmark NTCD-M3 data to be presented at Anaerobe
3rd May 20227:00 amRNSDestiny Pharma appoints Dr Yuri Martina as CMO
27th Apr 20223:34 pmRNSPosting of Annual Report and Notice of AGM
26th Apr 20223:30 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSAudited results for year ended 31 December 2021
4th Apr 20222:45 pmRNSNotice of Results
4th Apr 20222:37 pmRNSNotification of Major Holdings
31st Mar 20227:00 amRNSTo present data at ECCMID Congress
28th Mar 202211:30 amRNSResult of General Meeting and Total Voting Rights
25th Mar 20227:00 amRNSResult of Open Offer
22nd Mar 202210:30 amRNSExercise of Options and Total Voting Rights
8th Mar 202212:30 pmRNSFundraising
8th Feb 20227:00 amRNSPositive feedback from EMA on XF-73 Nasal gel Ph 3
1st Feb 20224:11 pmRNSExercise of Options and Total Voting Rights
1st Feb 20227:00 amRNSPositive data in XF-73 Dermal study with NIAID
31st Jan 20222:30 pmRNSExercise of Options and Total Voting Rights
25th Jan 20227:00 amRNSGrant of share options
24th Jan 20227:00 amRNSClinical and commercial opportunity of NTCD-M3
21st Jan 20227:15 amRNSDestiny Pharma Lancet Report
17th Jan 20227:00 amRNSStrategy/Company/Ops Update
21st Dec 20214:35 pmRNSExercise of Options and Total Voting Rights
17th Dec 20219:46 amRNSGrant of share options
15th Nov 20212:26 pmRNSDirectorate Change
12345

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.